Grants per year
Personal profile
Education/Academic qualification
Clinical Investigation, MSc, Northwestern University
… → 2002
Medicine, MD, University of Regensburg
… → 1994
Fingerprint
Dive into the research topics where Jochen Hanns-Martin Lorch is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Grants
- 12 Active
-
Prot #ALE.C04.01: A Phase I/II, Open-Label, Multi-Center Study of ALE.C04 (anti-Claudin-1Antibody) as a Single Agent and in Combination with Pembrolizumab (anti-PD-1 antibody) in Adult Patients with Recurrent or Metastatic (R/M) Head and Neck Squamous Cel
Lorch, J.H.-M. (PD/PI)
Ergomed Clinical Research Inc., Alentis Therapeutics AG
7/19/24 → 7/19/27
Project: Research project
-
Prot #XL092-305: A Phase 2/3, Randomized, Double-blind, Controlled Study of Zanzalintinib (XL092) in Combination with Pembrolizumab vs Pembrolizumab in the First-line Treatment of Subjects with PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous
Lorch, J.H.-M. (PD/PI)
Quintiles, Inc., Exelixis Inc.
5/22/24 → 5/22/27
Project: Research project
-
Prot #TAK-676-1002: An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastat
Lorch, J.H.-M. (PD/PI)
Pharmaceutical Research Associates, Inc., Takeda Development Center Americas, Inc.
5/21/24 → 5/21/27
Project: Research project
-
Prot #XmAb808‐01: A Phase 1, First‐in‐Human, Dose‐Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®808 in Combination with Pembrolizumab in Selected Advanced Solid Tumors
Lorch, J.H.-M. (PD/PI)
ICON Clinical Research, LLC, Xencor, Inc.
7/20/23 → 7/20/26
Project: Research project
-
DNA Anchoring Strength Directly Correlates with Spherical Nucleic Acid-Based HPV E7 Cancer Vaccine Potency
Hwang, J., Dittmar, J. W., Kang, J., Ocampo, T., Evangelopoulos, M., Han, Z., Kudruk, S., Lorch, J. & Mirkin, C. A., Jun 26 2024, In: Nano letters. 24, 25, p. 7629-7636 8 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Uncommon molecular alterations in follicular-derived thyroid carcinoma: A single institution study
Alexiev, B. A., Vormittag-Nocito, E. R., Lorch, J., Yeldandi, A., Buttars, P. R. & Jennings, L. J., Jun 2024, In: Pathology Research and Practice. 258, 155355.Research output: Contribution to journal › Article › peer-review
-
Smart Nanocarriers for the Targeted Delivery of Therapeutic Nucleic Acid for Cancer Immunotherapy
Baker, A., Lorch, J., VanderWeele, D. & Zhang, B., Jun 2023, In: Pharmaceutics. 15, 6, 1743.Research output: Contribution to journal › Review article › peer-review
Open Access4 Scopus citations -
Thyroid Cancers
Sehgal, K. & Lorch, J. H., Jan 1 2023, Cancer Consult: Expertise in Clinical Practice, Volume 1: Solid Tumors and Supportive Care. wiley, Vol. 1. p. 39-50 12 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter
-
A Robust Method for Perfusable Microvascular Network Formation In Vitro
Wan, Z., Zhong, A. X., Zhang, S., Pavlou, G., Coughlin, M. F., Shelton, S. E., Nguyen, H. T., Lorch, J. H., Barbie, D. A. & Kamm, R. D., Jun 30 2022, In: Small Methods. 6, 6, 2200143.Research output: Contribution to journal › Article › peer-review
Open Access29 Scopus citations